Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples